{
    "title": "109_hr5975",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Prescription Drug Comparative \nEffectiveness Act of 2006''.\n\nSEC. 2. RESEARCH AND STUDY ON EFFECTIVENESS OF CERTAIN PRESCRIPTION \n              DRUGS.\n\n    (a) In General.--\n            (1) Research.--The Director of the Agency for Healthcare \n        Research and Quality, in consultation with the Director of the \n        National Institutes of Health, shall conduct or support \n        research, which may include clinical research, to develop valid \n        scientific evidence regarding comparative clinical \n        effectiveness, outcomes, and appropriateness of prescription \n        drugs, medical devices, and procedures. In conducting or \n        supporting such research, particular consideration shall be \n        given to treatments that involve high volume, high cost, or \n        high risk to patients.\n            (2) Systematic reviews.--\n                    (A) In general.--The Director of the Agency for \n                Healthcare Research and Quality shall conduct or \n                support systematic reviews of existing evidence \n                regarding comparative clinical effectiveness, outcomes, \n                and appropriateness of prescription drugs, medical \n                devices, and procedures. In conducting or supporting \n                such reviews, particular consideration shall be given \n                to treatments that involve high volume, high cost, or \n                high risk to patients.\n                    (B) Better clinician and patient information on \n                safety.--Within 12 months of the date of the enactment \n                of this Act, the Secretary of Health and Human \n                Services, in consultation with the Director of the \n                Agency for Healthcare Research and Quality, the \n                Commissioner of Food and Drugs, and the Director of the \n                National Institutes of Health, shall develop a \n                coordinated plan for research on the most appropriate \n                methods for measuring and comparing adverse events \n                associated with pharmaceuticals and other medical and \n                surgical treatments so that clinicians and patients can \n                evaluate the comparative safety as well as the \n                comparative clinical effectiveness of the alternative \n                treatment options.\n    (b) Annual Report.--Each year the Director of the Agency for \nHealthcare Research and Quality shall prepare a report on the results \nof the research, studies, and analyses conducted under this section and \nsubmit the report to the following:\n            (1) The Congress.\n            (2) The Secretary of Defense.\n            (3) The Secretary of Health and Human Services.\n            (4) The Secretary of Veterans Affairs.\n            (5) The Administrator of the Centers for Medicare & \n        Medicaid Services.\n            (6) The Director of the Indian Health Service.\n            (7) The Director of the National Institutes of Health.\n            (8) The Director of the Office of Personnel Management.\n    (c) Reports for Practitioners.--As soon as possible, but not later \nthan a year after the completion of any systemic review conducted \npursuant to subsection (a)(2), the Director of the Agency for \nHealthcare Research and Quality shall--\n            (1) prepare a report on the results of such systemic review \n        for the purpose of informing health care practitioners; and\n            (2) identify treatment options for which comparative \n        clinical effectiveness judgments could not be reached due to \n        insufficient evidence and make such identifications available \n        to the Director of the National Institutes of Health and other \n        entities funding research.\n    (d) Information for Patients.--The Director of the Agency for \nHealthcare Research and Quality shall create a version of each report \nprepared for practitioners under subsection (c)(1) in a form that is \neasily understood by the individuals receiving the treatments involved.\n    (e) Availability.--The Director of the Agency for Healthcare \nResearch and Quality--\n            (1) shall publish on the Agency's Internet site, and \n        through other means that will facilitate access by \n        practitioners, each report prepared under subsection (b), (c), \n        or (d); and\n            (2) make the information in such reports available to the \n        public through easily accessible and searchable electronic \n        mechanisms, and in hard copy formats as appropriate.\n    (f) Accountability.--In carrying out this subsection, the Secretary \nof Health and Human Services shall implement activities in a manner \nthat makes publicly available all scientific evidence relied upon and \nthe methodologies employed, provided such evidence and method are not \nprotected from public disclosure by section 1905 of title 18, United \nStates Code, or other applicable law, so that the results of the \nresearch, analyses, or syntheses involved can be evaluated and \nreplicated.\n    (g) Authorization of Appropriations.--To carry out this section, \nthere are authorized to be appropriated to the Agency for Healthcare \nResearch and Quality and the National Institutes of Health $100,000,000 \nfor fiscal year 2007 and such sums as may be necessary for fiscal year \n2008 and each subsequent fiscal year."
}